Cargando…

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS

OBJECTIVE: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of nation...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Lorene M., Wallin, Mitchell T., Marrie, Ruth Ann, Culpepper, W.J., Langer-Gould, Annette, Campbell, Jon, Buka, Stephen, Tremlett, Helen, Cutter, Gary, Kaye, Wendy, Wagner, Laurie, Larocca, Nicholas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442012/
https://www.ncbi.nlm.nih.gov/pubmed/30770422
http://dx.doi.org/10.1212/WNL.0000000000007044
_version_ 1783407637336948736
author Nelson, Lorene M.
Wallin, Mitchell T.
Marrie, Ruth Ann
Culpepper, W.J.
Langer-Gould, Annette
Campbell, Jon
Buka, Stephen
Tremlett, Helen
Cutter, Gary
Kaye, Wendy
Wagner, Laurie
Larocca, Nicholas G.
author_facet Nelson, Lorene M.
Wallin, Mitchell T.
Marrie, Ruth Ann
Culpepper, W.J.
Langer-Gould, Annette
Campbell, Jon
Buka, Stephen
Tremlett, Helen
Cutter, Gary
Kaye, Wendy
Wagner, Laurie
Larocca, Nicholas G.
author_sort Nelson, Lorene M.
collection PubMed
description OBJECTIVE: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. METHODS: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. RESULTS: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. CONCLUSIONS: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist.
format Online
Article
Text
id pubmed-6442012
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-64420122019-04-15 A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS Nelson, Lorene M. Wallin, Mitchell T. Marrie, Ruth Ann Culpepper, W.J. Langer-Gould, Annette Campbell, Jon Buka, Stephen Tremlett, Helen Cutter, Gary Kaye, Wendy Wagner, Laurie Larocca, Nicholas G. Neurology Views & Reviews OBJECTIVE: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. METHODS: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. RESULTS: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. CONCLUSIONS: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist. Lippincott Williams & Wilkins 2019-03-05 /pmc/articles/PMC6442012/ /pubmed/30770422 http://dx.doi.org/10.1212/WNL.0000000000007044 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Views & Reviews
Nelson, Lorene M.
Wallin, Mitchell T.
Marrie, Ruth Ann
Culpepper, W.J.
Langer-Gould, Annette
Campbell, Jon
Buka, Stephen
Tremlett, Helen
Cutter, Gary
Kaye, Wendy
Wagner, Laurie
Larocca, Nicholas G.
A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
title A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
title_full A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
title_fullStr A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
title_full_unstemmed A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
title_short A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
title_sort new way to estimate neurologic disease prevalence in the united states: illustrated with ms
topic Views & Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442012/
https://www.ncbi.nlm.nih.gov/pubmed/30770422
http://dx.doi.org/10.1212/WNL.0000000000007044
work_keys_str_mv AT nelsonlorenem anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT wallinmitchellt anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT marrieruthann anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT culpepperwj anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT langergouldannette anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT campbelljon anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT bukastephen anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT tremletthelen anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT cuttergary anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT kayewendy anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT wagnerlaurie anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT laroccanicholasg anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT nelsonlorenem newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT wallinmitchellt newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT marrieruthann newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT culpepperwj newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT langergouldannette newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT campbelljon newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT bukastephen newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT tremletthelen newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT cuttergary newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT kayewendy newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT wagnerlaurie newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT laroccanicholasg newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms
AT newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms